Boehringer Ingelheim inaugurates the Shanghai "Center of Competence"

Boehringer IngelheimBoehringer Ingelheim celebrated the inauguration of its new "Center of Competence" (CoC) in Shanghai. As part of the company's EUR 100 million expansion project in China, the CoC entails an investment of EUR 10 million and will specialise in optimising active pharmaceutical ingredients (APIs) and chemical intermediates procured in China. So far, more than 20 highly-qualified organic and analytical chemists have been recruited for the CoC.

"This reinforces our company's determination and commitment to continue investing in China," said Prof. Wolfram Carius, Member of the Board of Managing Directors of Boehringer Ingelheim and responsible for the Board Division Human Resources and Operations. "We attach great importance to the exchange with our Chinese partners. We have a long-term commitment to this market and we are driving innovation in the country's pharmaceutical industry."

The new CoC consists of the two departments Process Development (PD) and Quality Control (QC). The main functions of PD are to focus on the production process optimisation and the corresponding technology transfer to the company's partners within China in order to increase the production efficiency and precision.

David Preston, Chief Executive Officer of Boehringer Ingelheim China, said: "The inauguration of CoC is a milestone for Boehringer Ingelheim's development in China. By optimising the production process of our partners and securing the quality of the intermediates, China will play a stronger role in the company's global procurement efforts."

In 2009, the company announced a EUR 100 million expansion plan in China to expand its production capacity in Shanghai Zhangjiang High-Tech Park and to set up the center of competence which is now being opened.

About Boehringer Ingelheim in China
The laboratories of CoC are currently located at Waigaoqiao Free Trade Zone, Pudong, Shanghai. It covers an area of about 2,000 square meters. The CoC has been tested since May 2010 and is scheduled to be officially in operation in September 2010.

Boehringer Ingelheim set up its China branch office in March 1994. A year later, Boehringer Ingelheim International Trade (Shanghai) Co., Ltd. was registered. In 1995, Boehringer Ingelheim Shanghai Pharmaceuticals Ltd. was established. In 2002, the company set up its production plant in Shanghai Zhangjiang High-tech Park. It has introduced a state-of-the-art manufacturing facility that strictly follows international GMP standards. Currently, the company has offices in Shanghai, Beijing, Guangzhou and Chengdu with around 2,000 employees.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees.Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is recognised for the excellence of its product pipeline covering therapeutic areas ranging from respiratory, cardiovascular to central nerve system medicines. In recent years, the company also successfully advanced its research in diseases including diabetes and tumors. In 2009, Boehringer Ingelheim posted net sales of EUR 12.7 billion while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development.

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...